{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:44:18Z","timestamp":1783748658471,"version":"3.55.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001146","name":"Greenwall Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001146","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mass drug administration (MDA) is a strategy to improve health at the population level through widespread delivery of medicine in a community. We surveyed the literature to summarize the benefits and potential risks associated with MDA of antibacterials, focusing predominantly on azithromycin as it has the greatest evidence base.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>High-quality evidence from randomized controlled trials (RCTs) indicate that MDA-azithromycin is effective in reducing the prevalence of infection due to yaws and trachoma. In addition, RCTs suggest that MDA-azithromycin reduces under-five mortality in certain low-resource settings that have high childhood mortality rates at baseline. This reduction in mortality appears to be sustained over time with twice-yearly MDA-azithromycin, with the greatest effect observed in children\u2009&lt;\u20091\u00a0year of age. In addition, observational data suggest that infections such as skin and soft tissue infections, rheumatic heart disease, acute respiratory illness, diarrheal illness, and malaria may all be treated by azithromycin and thus incidentally impacted by MDA-azithromycin. However, the mechanism by which MDA-azithromycin reduces childhood mortality remains unclear. Verbal autopsies performed in MDA-azithromycin childhood mortality studies have produced conflicting data and are underpowered to answer this question. In addition to benefits, there are several important risks associated with MDA-azithromycin. Direct adverse effects potentially resulting from MDA-azithromycin include gastrointestinal side effects, idiopathic hypertrophic pyloric stenosis, cardiovascular side effects, and increase in chronic diseases such as asthma and obesity. Antibacterial resistance is also a risk associated with MDA-azithromycin and has been reported for both gram-positive and enteric organisms. Further, there is the risk for cross-resistance with other antibacterial agents, especially clindamycin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Evidence shows that MDA-azithromycin programs may be beneficial for reducing trachoma, yaws, and mortality in children\u2009&lt;\u20095\u00a0years of age in certain under-resourced settings. However, there are significant potential risks that need to be considered when deciding how, when, and where to implement these programs. Robust systems to monitor benefits as well as adverse effects and antibacterial resistance are warranted in communities where MDA-azithromycin programs are implemented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s40249-022-00998-6","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T07:02:53Z","timestamp":1656572573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks"],"prefix":"10.1186","volume":"11","author":[{"given":"Robert J.","family":"Rolfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassaan","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6012-7271","authenticated-orcid":false,"given":"L. Gayani","family":"Tillekeratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"issue":"1645","key":"998_CR1","doi-asserted-by":"publisher","first-page":"20130434","DOI":"10.1098\/rstb.2013.0434","volume":"369","author":"JP Webster","year":"2014","unstructured":"Webster JP, Molyneux DH, Hotez PJ, Fenwick A. The contribution of mass drug administration to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014;369(1645):20130434.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"998_CR2","unstructured":"World Health Organization. WHO guideline on mass drug administration of azithromycin to children under five years of age to promote child survival. Geneva: 2020."},{"key":"998_CR3","unstructured":"World Health Organization. A road map for neglected tropical diseases 2021\u20132030. Geneva: 2020."},{"key":"998_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41551-020-00658-w","volume":"4","author":"N Pardi","year":"2020","unstructured":"Pardi N, Weissman D. Development of vaccines and antivirals for combating viral pandemics. Nat Biomed Eng. 2020;4:1128\u201333.","journal-title":"Nat Biomed Eng"},{"issue":"9","key":"998_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2009.1266","volume":"302","author":"TC Porco","year":"2009","unstructured":"Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA. 2009;302(9):962\u20138.","journal-title":"JAMA"},{"issue":"5","key":"998_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007315","volume":"13","author":"II Bogoch","year":"2019","unstructured":"Bogoch II, Utzinger J, Lo NC, Andrews JR. Antibacterial mass drug administration for child mortality reduction: opportunities, concerns, and possible next steps. PLoS Negl Trop Dis. 2019;13(5): e0007315.","journal-title":"PLoS Negl Trop Dis"},{"key":"998_CR7","unstructured":"World Health Organization. Evaluation of the WHO neglected tropical diseases programme. Geneva: 2019."},{"issue":"17","key":"998_CR8","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1056\/NEJMoa1715474","volume":"378","author":"JD Keenan","year":"2018","unstructured":"Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, et al. Azithromycin to reduce childhood mortality in sub-Saharan Africa. N Engl J Med. 2018;378(17):1583\u201392.","journal-title":"N Engl J Med"},{"issue":"23","key":"998_CR9","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1817213","volume":"380","author":"JD Keenan","year":"2019","unstructured":"Keenan JD, Arzika AM, Maliki R, Boubacar N, Elh Adamou S, Moussa Ali M, et al. Longer-term assessment of azithromycin for reducing childhood mortality in Africa. N Engl J Med. 2019;380(23):2207\u201314.","journal-title":"N Engl J Med"},{"issue":"5","key":"998_CR10","doi-asserted-by":"publisher","first-page":"750","DOI":"10.2165\/00003495-199244050-00007","volume":"44","author":"DH Peters","year":"1992","unstructured":"Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992;44(5):750\u201399.","journal-title":"Drugs"},{"issue":"9","key":"998_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003016","volume":"8","author":"K Asiedu","year":"2014","unstructured":"Asiedu K, Fitzpatrick C, Jannin J. Eradication of yaws: historical efforts and achieving WHO\u2019s 2020 target. PLoS Negl Trop Dis. 2014;8(9): e3016.","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"998_CR12","first-page":"CD001860","volume":"9","author":"JR Evans","year":"2019","unstructured":"Evans JR, Solomon AW, Kumar R, Perez \u00c1, Singh BP, Srivastava RM, et al. Antibiotics for trachoma. Cochrane Database Syst Rev. 2019;9(9):CD001860.","journal-title":"Cochrane Database Syst Rev"},{"key":"998_CR13","unstructured":"World Health Organization. Trachoma 2021. Available from: https:\/\/www.who.int\/trachoma\/epidemiology\/en\/. Accessed March 7 2021."},{"issue":"20","key":"998_CR14","first-page":"189","volume":"87","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. Eradication of yaws\u2014the Morges strategy. Wkly Epidemiol Rec. 2012;87(20):189\u201394.","journal-title":"Wkly Epidemiol Rec"},{"key":"998_CR15","unstructured":"World Health Organization. Weekly epidemiological record. 2020;30(95):349\u201360."},{"issue":"6","key":"998_CR16","first-page":"743","volume":"64","author":"A Amza","year":"2017","unstructured":"Amza A, Kadri B, Nassirou B, Cotter SY, Stoller NE, Zhou Z, et al. A cluster-randomized trial to assess the efficacy of targeting trachoma treatment to children. Clin Infect Dis. 2017;64(6):743\u201350.","journal-title":"Clin Infect Dis"},{"issue":"5 Suppl","key":"998_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4269\/ajtmh.2003.69.5_suppl_1.0690033","volume":"69","author":"SP Mariotti","year":"2003","unstructured":"Mariotti SP, Pararajasegaram R, Resnikoff S. Trachoma: looking forward to Global Elimination of Trachoma by 2020 (GET 2020). Am J Trop Med Hyg. 2003;69(5 Suppl):33\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"998_CR18","unstructured":"The Task Force for Global Health. International Trachoma Initiative 2020. Available from: https:\/\/www.trachoma.org\/. Accessed March 6 2021."},{"issue":"6","key":"998_CR19","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1016\/S2214-109X(15)00011-X","volume":"3","author":"O Mitj\u00e0","year":"2015","unstructured":"Mitj\u00e0 O, Marks M, Konan DJ, Ayelo G, Gonzalez-Beiras C, Boua B, et al. Global epidemiology of yaws: a systematic review. Lancet Glob Health. 2015;3(6):e324\u201331.","journal-title":"Lancet Glob Health"},{"key":"998_CR20","unstructured":"Organization WH. Yaws Geneva2021. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/yaws. Accessed March 6 2021."},{"issue":"1","key":"998_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005154","volume":"11","author":"C Kwakye-Maclean","year":"2017","unstructured":"Kwakye-Maclean C, Agana N, Gyapong J, Nortey P, Adu-Sarkodie Y, Aryee E, et al. A single dose oral azithromycin versus intramuscular benzathine penicillin for the treatment of yaws-a randomized non inferiority trial in Ghana. PLoS Negl Trop Dis. 2017;11(1): e0005154.","journal-title":"PLoS Negl Trop Dis"},{"issue":"9813","key":"998_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(11)61624-3","volume":"379","author":"O Mitj\u00e0","year":"2012","unstructured":"Mitj\u00e0 O, Hays R, Ipai A, Penias M, Paru R, Fagaho D, et al. Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial. Lancet. 2012;379(9813):342\u20137.","journal-title":"Lancet"},{"key":"998_CR23","unstructured":"Nations U. Transforming our world: the 2030 agenda for sustainable development. 2015."},{"key":"998_CR24","unstructured":"UNICEF. Under-five mortality 2020. Available from: https:\/\/data.unicef.org\/topic\/child-survival\/under-five-mortality\/. Accessed March 4 2021."},{"issue":"7","key":"998_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/cid\/cir069","volume":"52","author":"JD Keenan","year":"2011","unstructured":"Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis. 2011;52(7):883\u20138.","journal-title":"Clin Infect Dis"},{"issue":"23","key":"998_CR26","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa1811400","volume":"380","author":"D Chandramohan","year":"2019","unstructured":"Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, et al. Effect of adding azithromycin to seasonal malaria chemoprevention. N Engl J Med. 2019;380(23):2197\u2013206.","journal-title":"N Engl J Med"},{"issue":"11","key":"998_CR27","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/INF.0000000000001992","volume":"37","author":"KS O'Brien","year":"2018","unstructured":"O\u2019Brien KS, Cotter SY, Amza A, Kadri B, Nassirou B, Stoller NE, et al. Childhood mortality after mass distribution of azithromycin: a secondary analysis of the PRET cluster-randomized trial in Niger. Pediatr Infect Dis. 2018;37(11):1082\u20136.","journal-title":"Pediatr Infect Dis"},{"issue":"11","key":"998_CR28","doi-asserted-by":"publisher","first-page":"e1569","DOI":"10.1016\/S2214-109X(21)00347-8","volume":"9","author":"PB Pavlinac","year":"2021","unstructured":"Pavlinac PB, Singa BO, Tickell KD, Brander RL, McGrath CJ, Amondi M, et al. Azithromycin for the prevention of rehospitalisation and death among Kenyan children being discharged from hospital: a double-blind, placebo-controlled, randomised controlled trial. Lancet Glob Health. 2021;9(11):e1569\u201378.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"998_CR29","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.4269\/ajtmh.19-0622","volume":"103","author":"JD Hart","year":"2020","unstructured":"Hart JD, Kalua K, Keenan JD, Lietman TM, Bailey RL. Cost-effectiveness of mass treatment with azithromycin for reducing child mortality in Malawi: secondary analysis from the MORDOR trial. Am J Trop Med Hyg. 2020;103(3):1283\u201390.","journal-title":"Am J Trop Med Hyg"},{"key":"998_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/cid\/ciz1220","volume":"74","author":"RL Brander","year":"2020","unstructured":"Brander RL, Weaver MR, Pavlinac PB, John-Stewart GC, Hawes SE, Walson JL. Projected impact and cost-effectiveness of community-based versus targeted azithromycin administration strategies for reducing child mortality in sub-Saharan Africa. Clin Infect Dis. 2020;74:375.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"998_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1164\/rccm.201903-0706ED","volume":"200","author":"T Welte","year":"2019","unstructured":"Welte T. Azithromycin: the holy grail to prevent exacerbations in chronic respiratory disease? Am J Respir Crit Care Med. 2019;200(3):269\u201370.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"998_CR32","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1016\/S2214-109X(19)30540-6","volume":"8","author":"JD Keenan","year":"2020","unstructured":"Keenan JD, Arzika AM, Maliki R, Elh Adamou S, Ibrahim F, Kiemago M, et al. Cause-specific mortality of children younger than 5 years in communities receiving biannual mass azithromycin treatment in Niger: verbal autopsy results from a cluster-randomised controlled trial. Lancet Glob Health. 2020;8(2):e288\u201395.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"998_CR33","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.4269\/ajtmh.19-0500","volume":"103","author":"EM Bloch","year":"2020","unstructured":"Bloch EM, Munoz B, Weaver J, Mrango Z, Lietman TM, West SK. Impact of biannual azithromycin on anemia in preschool children in Kilosa District, Tanzania: a cluster-randomized clinical trial. Am J Trop Med Hyg. 2020;103(3):1311\u20134.","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"998_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/tmi.13390","volume":"25","author":"GR Gore-Langton","year":"2020","unstructured":"Gore-Langton GR, Cairns M, Compaore YD, Sagara I, Kuepfer I, Zongo I, et al. Effect of adding azithromycin to the antimalarials used for seasonal malaria chemoprevention on the nutritional status of African children. Trop Med Int Health. 2020;25(6):740\u201350.","journal-title":"Trop Med Int Health"},{"issue":"1","key":"998_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4269\/ajtmh.2012.12-0284","volume":"88","author":"A Amza","year":"2013","unstructured":"Amza A, Kadri B, Nassirou B, Stoller NE, Yu SN, Zhou Z, et al. A cluster-randomized controlled trial evaluating the effects of mass azithromycin treatment on growth and nutrition in Niger. Am J Trop Med Hyg. 2013;88(1):138\u201343.","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"998_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007442","volume":"13","author":"JD Keenan","year":"2019","unstructured":"Keenan JD, Gebresillasie S, Stoller NE, Haile BA, Tadesse Z, Cotter SY, et al. Linear growth in preschool children treated with mass azithromycin distributions for trachoma: a cluster-randomized trial. PLoS Negl Trop Dis. 2019;13(6): e0007442.","journal-title":"PLoS Negl Trop Dis"},{"key":"998_CR37","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1186\/1471-2458-14-1176","volume":"14","author":"SE Burr","year":"2014","unstructured":"Burr SE, Hart J, Edwards T, Harding-Esch EM, Holland MJ, Mabey DC, et al. Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health. 2014;14:1176.","journal-title":"BMC Public Health"},{"issue":"12","key":"998_CR38","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s00228-020-02956-3","volume":"76","author":"L Zeng","year":"2020","unstructured":"Zeng L, Xu P, Choonara I, Bo Z, Pan X, Li W, et al. Safety of azithromycin in pediatrics: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020;76(12):1709\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"998_CR39","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4269\/ajtmh.18-0781","volume":"100","author":"T Astale","year":"2019","unstructured":"Astale T, Sata E, Zerihun M, Nute AW, Stewart AEP, Chanyalew M, et al. Self-reported side effects following mass administration of azithromycin to eliminate trachoma in Amhara, Ethiopia: results from a region-wide population-based survey. Am J Trop Med Hyg. 2019;100(3):696\u20139.","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"998_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008194","volume":"5","author":"C Smith","year":"2015","unstructured":"Smith C, Egunsola O, Choonara I, Kotecha S, Jacqz-Aigrain E, Sammons H. Use and safety of azithromycin in neonates: a systematic review. BMJ Open. 2015;5(12): e008194.","journal-title":"BMJ Open"},{"issue":"12","key":"998_CR41","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00383-016-3971-5","volume":"32","author":"L Murchison","year":"2016","unstructured":"Murchison L, De Coppi P, Eaton S. Post-natal erythromycin exposure and risk of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis. Pediatr Surg Int. 2016;32(12):1147\u201352.","journal-title":"Pediatr Surg Int"},{"issue":"3","key":"998_CR42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1542\/peds.2014-2026","volume":"135","author":"MD Eberly","year":"2015","unstructured":"Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early infancy and pyloric stenosis. Pediatrics. 2015;135(3):483\u20138.","journal-title":"Pediatrics"},{"issue":"1","key":"998_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/ajps.AJPS_51_16","volume":"15","author":"UO Ezomike","year":"2018","unstructured":"Ezomike UO, Ekenze SO, Amah CC, Nwankwo EP, Obianyo NE. Infantile hypertrophic pyloric stenosis\u2014our experience and challenges in a developing country. Afr J Paediatr Surg. 2018;15(1):26\u201330.","journal-title":"Afr J Paediatr Surg"},{"issue":"11","key":"998_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006950","volume":"12","author":"CE Oldenburg","year":"2018","unstructured":"Oldenburg CE, Arzika AM, Maliki R, Kane MS, Lebas E, Ray KJ, et al. Safety of azithromycin in infants under six months of age in Niger: a community randomized trial. PLoS Negl Trop Dis. 2018;12(11): e0006950.","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"998_CR45","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.hrthm.2020.05.014","volume":"17","author":"E Chorin","year":"2020","unstructured":"Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine\/azithromycin. Heart Rhythm. 2020;17(9):1425\u201333.","journal-title":"Heart Rhythm"},{"issue":"9","key":"998_CR46","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","volume":"5","author":"NJ Mercuro","year":"2020","unstructured":"Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036\u201341.","journal-title":"JAMA Cardiol"},{"issue":"12","key":"998_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017144","volume":"9","author":"A Ramireddy","year":"2020","unstructured":"Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, et al. Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: implications for QT interval monitoring. J Am Heart Assoc. 2020;9(12): e017144.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"998_CR48","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1017\/S1047951120002425","volume":"30","author":"T Tuncer","year":"2020","unstructured":"Tuncer T, Karaci M, Boga A, Durmaz H, Guven S. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019. Cardiol Young. 2020;30(10):1482\u20135.","journal-title":"Cardiol Young"},{"key":"998_CR49","doi-asserted-by":"publisher","first-page":"10410","DOI":"10.1038\/ncomms10410","volume":"7","author":"K Korpela","year":"2016","unstructured":"Korpela K, Salonen A, Virta LJ, Kekkonen RA, Forslund K, Bork P, et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat Commun. 2016;7:10410.","journal-title":"Nat Commun"},{"issue":"3","key":"998_CR50","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1542\/peds.2008-1146","volume":"123","author":"F Marra","year":"2009","unstructured":"Marra F, Marra CA, Richardson K, Lynd LD, Kozyrskyj A, Patrick DM, et al. Antibiotic use in children is associated with increased risk of asthma. Pediatrics. 2009;123(3):1003\u201310.","journal-title":"Pediatrics"},{"issue":"10","key":"998_CR51","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jiph.2020.06.024","volume":"13","author":"C Kenyon","year":"2020","unstructured":"Kenyon C, Laumen J, Manoharan-Basil SS, Buyze J. Strong association between adolescent obesity and consumption of macrolides in Europe and the USA: an ecological study. J Infect Public Health. 2020;13(10):1517\u201321.","journal-title":"J Infect Public Health"},{"key":"998_CR52","unstructured":"Global Malaria Programme WHO. The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria. 2015."},{"issue":"4","key":"998_CR53","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.tim.2006.02.006","volume":"14","author":"C Baker-Austin","year":"2006","unstructured":"Baker-Austin C, Wright MS, Stepanauskas R, McArthur JV. Co-selection of antibiotic and metal resistance. Trends Microbiol. 2006;14(4):176\u201382.","journal-title":"Trends Microbiol"},{"issue":"10130","key":"998_CR54","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S0140-6736(18)30204-6","volume":"391","author":"O Mitj\u00e0","year":"2018","unstructured":"Mitj\u00e0 O, Godornes C, Houinei W, Kapa A, Paru R, Abel H, et al. Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study. Lancet. 2018;391(10130):1599\u2013607.","journal-title":"Lancet"},{"issue":"1","key":"998_CR55","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S1473-3099(18)30444-4","volume":"19","author":"KS O'Brien","year":"2019","unstructured":"O\u2019Brien KS, Emerson P, Hooper PJ, Reingold AL, Dennis EG, Keenan JD, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis. 2019;19(1):e14\u201325.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"998_CR56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12866-017-0982-x","volume":"17","author":"E Bojang","year":"2017","unstructured":"Bojang E, Jafali J, Perreten V, Hart J, Harding-Esch EM, Sillah A, et al. Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiol. 2017;17(1):75.","journal-title":"BMC Microbiol"},{"issue":"6","key":"998_CR57","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/cid\/ciy574","volume":"68","author":"M Marks","year":"2019","unstructured":"Marks M, Toloka H, Baker C, Kositz C, Asugeni J, Puiahi E, et al. Randomized trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo. Clin Infect Dis. 2019;68(6):927\u201333.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"998_CR58","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/ije\/dyu062","volume":"43","author":"JC Seidman","year":"2014","unstructured":"Seidman JC, Coles CL, Silbergeld EK, Levens J, Mkocha H, Johnson LB, et al. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. Int J Epidemiol. 2014;43(4):1105\u201313.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"998_CR59","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.4269\/ajtmh.19-0086","volume":"103","author":"EM Bloch","year":"2020","unstructured":"Bloch EM, Coles CL, Kasubi M, Weaver J, Mrango Z, Munoz B, et al. Biannual treatment of preschool children with single dose azithromycin to reduce mortality: impact on azithromycin resistance in the MORDOR trial in Tanzania. Am J Trop Med Hyg. 2020;103(3):1301\u20137.","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"998_CR60","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-019-0533-0","volume":"25","author":"T Doan","year":"2019","unstructured":"Doan T, Hinterwirth A, Worden L, Arzika AM, Maliki R, Abdou A, et al. Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat Med. 2019;25(9):1370\u20136.","journal-title":"Nat Med"},{"issue":"20","key":"998_CR61","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2002606","volume":"383","author":"T Doan","year":"2020","unstructured":"Doan T, Worden L, Hinterwirth A, Arzika AM, Maliki R, Abdou A, et al. Macrolide and nonmacrolide resistance with mass azithromycin distribution. N Engl J Med. 2020;383(20):1941\u201350.","journal-title":"N Engl J Med"},{"key":"998_CR62","doi-asserted-by":"crossref","unstructured":"Fyfe C, Grossman TH, Kerstein K, Sutcliffe J. Resistance to macrolide antibiotics in public health pathogens. Cold Spring Harb Perspect Med. 2016;6(10).","DOI":"10.1101\/cshperspect.a025395"},{"issue":"23","key":"998_CR63","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMc1901535","volume":"380","author":"T Doan","year":"2019","unstructured":"Doan T, Arzika AM, Hinterwirth A, Maliki R, Zhong L, Cummings S, et al. Macrolide resistance in MORDOR I\u2014a cluster-randomized trial in Niger. N Engl J Med. 2019;380(23):2271\u20133.","journal-title":"N Engl J Med"},{"issue":"1","key":"998_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40249-020-0630-9","volume":"9","author":"D Engels","year":"2020","unstructured":"Engels D, Zhou XN. Neglected tropical diseases: an effective global response to local poverty-related disease priorities. Infect Dis Poverty. 2020;9(1):10.","journal-title":"Infect Dis Poverty"},{"issue":"3","key":"998_CR65","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.4269\/ajtmh.19-0328","volume":"103","author":"CE Oldenburg","year":"2020","unstructured":"Oldenburg CE, Arzika AM, Maliki R, Lin Y, O\u2019Brien KS, Keenan JD, et al. Optimizing the number of child deaths averted with mass azithromycin distribution. Am J Trop Med Hyg. 2020;103(3):1308\u201310.","journal-title":"Am J Trop Med Hyg"},{"key":"998_CR66","unstructured":"The Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. 2014."},{"issue":"3","key":"998_CR67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.trstmh.2005.07.021","volume":"100","author":"A Boutayeb","year":"2006","unstructured":"Boutayeb A. The double burden of communicable and non-communicable diseases in developing countries. Trans R Soc Trop Med Hyg. 2006;100(3):191\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"998_CR68","unstructured":"World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report- Early Implementation 2020. 2020."},{"issue":"7","key":"998_CR69","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1093\/cid\/ciz893","volume":"70","author":"I Mack","year":"2020","unstructured":"Mack I, Sharland M, Berkley JA, Klein N, Malhotra-Kumar S, Bielicki J. Antimicrobial resistance following azithromycin mass drug administration: potential surveillance strategies to assess public health impact. Clin Infect Dis. 2020;70(7):1501\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"998_CR70","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-52.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"998_CR71","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S1473-3099(18)30790-4","volume":"19","author":"L Romani","year":"2019","unstructured":"Romani L, Marks M, Sokana O, Nasi T, Kamoriki B, Cordell B, et al. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lancet Infect Dis. 2019;19(5):510\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"998_CR72","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/cid\/ciz444","volume":"70","author":"M Marks","year":"2020","unstructured":"Marks M, Romani L, Sokana O, Neko L, Harrington R, Nasi T, et al. Prevalence of scabies and impetigo 3 years after mass drug administration with ivermectin and azithromycin. Clin Infect Dis. 2020;70(8):1591\u20135.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"998_CR73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1086\/341414","volume":"35","author":"AM Fry","year":"2002","unstructured":"Fry AM, Jha HC, Lietman TM, Chaudhary JS, Bhatta RC, Elliott J, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis. 2002;35(4):395\u2013402.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"998_CR74","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/cid\/cis847","volume":"55","author":"ST Shulman","year":"2012","unstructured":"Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):1279\u201382.","journal-title":"Clin Infect Dis"},{"key":"998_CR75","unstructured":"World Health Organization. WHO Technical Report Series- Rheumatic Fever and Rheumatic Heart Disease. Report of a WHO Expert Consultation Geneva, 29 October-1 November 2001. Geneva: 2004."},{"issue":"8","key":"998_CR76","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1086\/382879","volume":"38","author":"IA Guchev","year":"2004","unstructured":"Guchev IA, Gray GC, Klochkov OI. Two regimens of azithromycin prophylaxis against community-acquired respiratory and skin\/soft-tissue infections among military trainees. Clin Infect Dis. 2004;38(8):1095\u2013101.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"998_CR77","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/INF.0b013e31824155c9","volume":"31","author":"CL Coles","year":"2012","unstructured":"Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J. 2012;31(4):341\u20136.","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"998_CR78","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/00006454-199911000-00003","volume":"18","author":"CJ Whitty","year":"1999","unstructured":"Whitty CJ, Glasgow KW, Sadiq ST, Mabey DC, Bailey R. Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. Pediatr Infect Dis J. 1999;18(11):955\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"998_CR79","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4269\/ajtmh.2011.11-0046","volume":"85","author":"CL Coles","year":"2011","unstructured":"Coles CL, Seidman JC, Levens J, Mkocha H, Munoz B, West S. Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. Am J Trop Med Hyg. 2011;85(4):691\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"998_CR80","doi-asserted-by":"crossref","unstructured":"van Eijk AM, Terlouw DJ. Azithromycin for treating uncomplicated malaria. Cochrane Database Syst Rev. 2011(2):CD006688.","DOI":"10.1002\/14651858.CD006688.pub2"},{"issue":"6","key":"998_CR81","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3201\/eid2006.131302","volume":"20","author":"SE Schachterle","year":"2014","unstructured":"Schachterle SE, Mtove G, Levens JP, Clemens E, Shi L, Raj A, et al. Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania. Emerg Infect Dis. 2014;20(6):941\u20139.","journal-title":"Emerg Infect Dis"},{"key":"998_CR82","unstructured":"World Health Organization. WHO guidelines for the treatment of Treponema pallidum (syphilis). Geneva: 2016."},{"issue":"1","key":"998_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.olq.0000148297.48590.d8","volume":"32","author":"MG Kiddugavu","year":"2005","unstructured":"Kiddugavu MG, Kiwanuka N, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, et al. Effectiveness of syphilis treatment using azithromycin and\/or benzathine penicillin in Rakai, Uganda. Sex Transm Dis. 2005;32(1):1\u20136.","journal-title":"Sex Transm Dis"},{"key":"998_CR84","unstructured":"Chlamydial Infections: Centers for Disease Control and Prevention; 2015. Available from: https:\/\/www.cdc.gov\/std\/tg2015\/chlamydia.htm. Acccessed June 5 2021."},{"issue":"4","key":"998_CR85","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/sextrans-2015-052439","volume":"92","author":"M Marks","year":"2016","unstructured":"Marks M, Bottomley C, Tome H, Pitakaka R, Butcher R, Sokana O, et al. Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands. Sex Transm Infect. 2016;92(4):261\u20135.","journal-title":"Sex Transm Infect"},{"issue":"3","key":"998_CR86","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4269\/ajtmh.19-0613","volume":"103","author":"JD Hart","year":"2020","unstructured":"Hart JD, Kalua K, Keenan JD, Lietman TM, Bailey RL. Effect of mass treatment with azithromycin on causes of death in children in Malawi: secondary analysis from the MORDOR trial. Am J Trop Med Hyg. 2020;103(3):1319\u201328.","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"998_CR87","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.4269\/ajtmh.19-0619","volume":"103","author":"JD Hart","year":"2020","unstructured":"Hart JD, Samikwa L, Sikina F, Kalua K, Keenan JD, Lietman TM, et al. Effects of biannual azithromycin mass drug administration on malaria in Malawian children: a cluster-randomized trial. Am J Trop Med Hyg. 2020;103(3):1329\u201334.","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"998_CR88","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.4269\/ajtmh.18-1003","volume":"103","author":"TC Porco","year":"2020","unstructured":"Porco TC, Oldenburg CE, Arzika AM, Kalua K, Mrango Z, Cook C, et al. Efficacy of mass azithromycin distribution for reducing childhood mortality across geographic regions. Am J Trop Med Hyg. 2020;103(3):1291\u20134.","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"998_CR89","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4269\/ajtmh.18-0846","volume":"100","author":"CE Oldenburg","year":"2019","unstructured":"Oldenburg CE, Arzika AM, Amza A, Gebre T, Kalua K, Mrango Z, et al. Mass azithromycin distribution to prevent childhood mortality: a pooled analysis of cluster-randomized trials. Am J Trop Med Hyg. 2019;100(3):691\u20135.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"998_CR90","doi-asserted-by":"publisher","first-page":"679","DOI":"10.4269\/ajtmh.19-0944","volume":"103","author":"S Hema-Ouangraoua","year":"2020","unstructured":"Hema-Ouangraoua S, Zongo I, Kabore NF, Fr\u00e9d\u00e9ric N, Yerbanga RS, Tinto H, et al. Serotype profile of nasopharyngeal isolates of Streptococcus pneumoniae obtained from children in Burkina Faso before and after mass administration of azithromycin. Am J Trop Med Hyg. 2020;103(2):679\u201383.","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"998_CR91","doi-asserted-by":"publisher","first-page":"815","DOI":"10.4269\/ajtmh.17-0022","volume":"97","author":"EM Bloch","year":"2017","unstructured":"Bloch EM, West SK, Mabula K, Weaver J, Mrango Z, Munoz B, et al. Antibiotic resistance in young children in Kilosa District, Tanzania 4 years after mass distribution of azithromycin for trachoma control. Am J Trop Med Hyg. 2017;97(3):815\u20138.","journal-title":"Am J Trop Med Hyg"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-022-00998-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-022-00998-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-022-00998-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T07:07:11Z","timestamp":1656572831000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-022-00998-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["998"],"URL":"https:\/\/doi.org\/10.1186\/s40249-022-00998-6","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"5 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors of this paper have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}